The data demonstrate that TB202-3 and TB202-63 protected against weight loss, an indicator of disease severity, starting at 1 mg/kg in a hamster challenge model, and TB181-36 protected against weight loss at 5 mg/kg and 10 mg/kg, according to Twist. In comparison, control animals lost 12% of their body weight.
TB202-63 and TB202-3 are single-domain VHH (nanobody) candidates found through synthetic antibody discovery libraries for candidates that could bind to the SARS-CoV-2 S1 receptor. TB181-36 is an immunoglobulin G (IgG) antibody based on those found in individuals recovered from COVID-19.
The studies were conducted in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Vanderbilt University Medical Center. Twist plans to explore opportunities to further develop all three antibodies internally or with partners.
Copyright © 2020 scienceboard.net